Inflammation & Allergy-Drug Targets (Discontinued)

(Formerly Current Drug Targets - Inflammation & Allergy)

Kurt S Zaenker
Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448


The Treatment Targets of Asthma: From Laboratory to Clinic

Author(s): Cailong Fang, Chris J. Corrigan and Sun Ying

Affiliation: Department of Asthma, Allergy and Respiratory Science, 5th Floor, Tower Wing, Guy's Hospital, King's College London, London, SE1 9RT, UK.


Asthma is a chronic disease characterised by airways hyperresponsiveness, airways inflammation, airways remodelling and reversible airways obstruction. Airway structural cells, recruited inflammatory cells and many mediators such as cytokines, chemokines and adhesion molecules are involved in the pathogenesis of asthma. Although asthma is treatable in most, but not all patients by currently available drugs, no treatment is preventive or curative and the disease has reached epidemic proportions worldwide and its incidence is continuing to increase. Many thousands have chronic, severe asthma and suffer daily symptoms making it imperative that we continue to improve our understanding of the mechanisms of asthma particularly related to airway inflammation and remodelling, the hallmarks of asthma, and to identify new therapeutic targets. In this review we will discuss current drugs and potential targets in the treatment of asthma.

Keywords: Asthma, airway inflammation, remodelling, common therapy, new targets

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [119 - 128]
Pages: 10
DOI: 10.2174/187152808785107624
Price: $58